Revolutionize Precision Medicine

We unravel disease mechanisms
by identifying aberrant activities
of cell signaling pathways

news

InnoSIGN starts offering OncoSIGNal pathway profiling services for clinical use in the US

news

InnoSIGN receives grant of almost €700K for ovarian cancer multicenter trial

news

Institut Gustave Roussy: OncoSIGNal predicts resistance to AR targeted drugs in mCR prostate cancer

events

Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers

events

Racial differences in estrogen receptor signaling pathway activity in breast cancer patients